oral tirzepatide Dissolving Tablets - Needle-Free GLP-1/GIP Weight Loss The dual Oral Tirzepatide Pill: FDA Status
Description
announced that it has submitted an IND application to the FDA for MBX 4291, a long-acting GLP-1/GIP receptor co-agonist prodrug targeting obesity, which received regulatory clearance in July
Weight loss achieved through GLP-1 medications has been associated with reductions in blood pressure, cholesterol levels, and inflammation, all contributing to a lower risk of cardiovascular disease
To date, according to FDA spokespeople, reports of side effects from taking compounded versions havent raised major alarms
The other authors report no conflicts of interest
Health Behav
Stay Extremely Well-Hydrated: Combat dry mouth by drinking water consistently throughout the day
